Cardiovascular Therapeutics

Research Article

Stroke Risk Status, Anticoagulation Treatment, and Quality-of-Life in Chinese Patients with Atrial Fibrillation: China Registry of Atrial Fibrillation (CRAF)

Table 3

The impact of anticoagulant and antiplatelet treatment on QoL assessed by the SF-36 questionnaire in patients with NVAF and VAF (mean scores and 95% CIs).


Domains	Anticoagulants	Antiplatelet Agents	No antithrombotic therapy	p-Value

Patients with NVAF
Physical functioning	57.29 (53.45, 61.13)	54.72 (50.94, 58.50)	53.71 (49.57, 57.85)	0.005
Physical role functioning	34.87 (27.48, 42.25)	32.03 (24.76, 39.30)	33.29 (25.33, 41.26)	0.2601
Bodily pain	72.55 (68.92, 76.18)	71.84 (68.27, 75.41)	73.60 (69.69, 77.51)	0.271
General health	41.76 (38.34, 45.18)	42.18 (38.82, 45.54)	38.40 (34.72, 42.09)	0.002
Vitality	61.54 (58.44, 64.64)	60.97 (57.93, 64.02)	59.13 (55.79, 62.47)	0.070
Social role functioning	59.57 (55.77, 63.38)	59.69 (55.94, 63.43)	58.67 (54.57, 62.78)	0.693
Emotional role functioning	59.35 (51.72, 66.98)	54.74 (47.23, 62.24)	54.41 (46.19, 62.63)	0.026
Mental health	67.92 (65.19, 70.65)	66.21 (63.53, 68.89)	66.11 (63.11, 69.12)	0.040
Patients with VAF
Physical functioning	43.70 (35.79, 51.61)	37.96 (29.58, 46.34)	34.69 (25.09, 44.29)	0.004
Physical role functioning	28.86 (10.57, 47.15)	20.99 (2.00, 39.98)	19.02 (−1.04, 39.08)	0.055
Bodily pain	59.92 (53.44, 66.40)	58.86 (51.91, 65.81)	54.46 (46.11, 62.80)	0.231
General health	36.27 (27.50, 45.04)	34.71 (25.60, 43.82)	31.96 (22.34, 41.59)	0.252
Vitality	46.61 (40.32, 52.90)	45.29 (38.62, 51.96)	40.54 (32.90, 48.18)	0.074
Social role functioning	49.44 (41.63, 57.25)	45.06 (36.78, 53.33)	42.46 (32.98, 51.94)	0.036
Emotional role functioning	44.51 (31.73, 57.30)	27.60 (13.90, 41.29)	35.68 (19.22, 52.14)	0.001
Mental health	53.25 (47.11, 59.39)	52.88 (46.38, 59.39)	49.02 (41.60, 56.44)	0.276

NVAF: non-valvular atrial fibrillation; QoL: quality of life; SF-36: Medical Outcomes Study Short-Form 36 Health Survey; VAF: valvular atrial fibrillation.
means p-values referring to differences among the 3 groups.
“a” indicates significant difference versus patients receiving antiplatelet drugs, and “b” indicates significant difference versus patients not on antithrombotic therapy.